send mail to support@abhimanu.com mentioning your email id and mobileno registered with us! if details not recieved
Resend Opt after 60 Sec.
By Loging in you agree to Terms of Services and Privacy Policy
Claim your free MCQ
Please specify
Sorry for the inconvenience but we’re performing some maintenance at the moment. Website can be slow during this phase..
Please verify your mobile number
Login not allowed, Please logout from existing browser
Please update your name
Subscribe to Notifications
Stay updated with the latest Current affairs and other important updates regarding video Lectures, Test Schedules, live sessions etc..
Your Free user account at abhipedia has been created.
Remember, success is a journey, not a destination. Stay motivated and keep moving forward!
Refer & Earn
Enquire Now
My Abhipedia Earning
Kindly Login to view your earning
Support
Context: Researchers at the Netherlands Cancer Institute have conducted a recent study to investigate drug resistance in cancer cells, focusing on resistance to a drug known as Taxol.
It is a complex and broad term used to describe a group of diseases characterised by the uncontrolled growth and spread of abnormal cells in the body.
These abnormal cells, known as cancer cells, have the ability to invade and destroy healthy tissues and organs.
In a healthy body, cells grow, divide, and die in a regulated manner, allowing for the normal functioning of tissues and organs.
However, in the case of cancer, certain genetic mutations or abnormalities disrupt this normal cell cycle, causing cells to divide and grow uncontrollably.
These cells can form a mass of tissue called a tumour.
Cancer cells are characterized by uncontrolled and rapid division.
Chemotherapeutic drugs aim to halt this proliferation, often triggering programmed cell death, known as apoptosis, in response to halted cell division.
However, this approach also damages healthy dividing cells, leading to adverse side effects.
Oncologists face the challenge of finding an effective drug dose that eliminates cancer cells while minimizing unbearable side effects for patients.
One approach has been the development of antibody-drug conjugates (ADCs) that target specific proteins found mainly on cancer cells, sparing non-cancerous cells.
P-gp Protein: Some cancer cells escape drug treatments by overexpressing a protein called P-gp (permeability glycoprotein), which acts as a pump, expelling toxic compounds, including chemotherapeutic agents.
ABCB1 Gene: The production of P-gp is controlled by the ABCB1 gene, and cells that produce excessive P-gp can flush out chemotherapy drugs, preventing them from accumulating at levels needed to trigger apoptosis.
Recent Findings: The study examined the sensitivity of cells to Taxol and identified that the location of the ABCB1 gene within the cell’s nucleus plays a crucial role.
Nuclear Envelope: In sensitive cells, the ABCB1 gene is located close to the nuclear envelope. In resistant cells, the gene has detached from the envelope and moved further inside the nucleus, resulting in a 100-fold increase in ABCB1 gene-related RNA.
LBR’s Influence: Researchers discovered that the presence or absence of a protein called Lamin B Receptor (LBR) affects the location of the ABCB1 gene.
Depletion of LBR: When LBR is depleted, cells can activate the ABCB1 gene when exposed to Taxol. However, the absence of the LBR gene itself does not immediately increase ABCB1 expression, indicating the involvement of additional factors.
Diverse Responses: Different cancer types exhibit varying responses to LBR depletion, highlighting the complex mechanisms governing gene expression and silencing.
Analogy: A simple analogy illustrates the diversity: Different bathrooms offer various options for drying clothes, and cancer cell types rely on different mechanisms to tether genes to the nuclear envelope.
These findings emphasize the need for further research into the diverse ways cancer cells express or suppress genes.
Understanding drug resistance mechanisms opens avenues for developing strategies to maintain the potency of anti-cancer drugs while minimizing side effects, ultimately benefiting patients on their path to recovery.
With reference to the chemotherapy of cancer cells, consider the following statements
It involves the targeting of rapidly dividing cancer cells, often leading to programmed cell death or apoptosis.
This cell death underlies the unpleasant side-effects of chemotherapy, such as painful inflammation of the oral cavity and the gut, and nausea, diarrhea, anemia, and hair loss.
It involves attaching drugs to antibodies designed to recognize proteins predominantly found in cancer cells.
How many of the above statements is/are correct?
Only One
Only Two
All Three
None
Only statements 1&2 are correct.
Chemotherapy is a fundamental cancer treatment but poses significant challenges.
Chemotherapy of cancer cells involves the targeting of rapidly dividing cancer cells, often leading to programmed cell death or apoptosis.
However, this mechanism also affects non-cancerous cells. Any tissue with a significant number of normal cells that are also dividing, such as cells in the digestive tract, the bone marrow, and hair follicles are also affected by chemotherapeutic agents and suffer apoptosis.
Researchers have developed Antibody-Drug Conjugates (ADCs) as a more targeted approach for certain cancer types.
Antibody-Drug Conjugates (ADCs) involve attaching drugs to antibodies designed to recognize proteins predominantly found in cancer cells.
Hence option 2nd is correct.
Access to prime resources